← Back to Search

Other

SM17 for Asthma

Phase 1
Recruiting
Research Sponsored by SinoMab BioScience Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up until follow-up (fu) visit/early termination (et) visit (14 and 28 days post-last dose)
Awards & highlights

Study Summary

This trial is a study to test a new drug, SM17, on humans to see if it is safe and has any effect.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~until follow-up (fu) visit/early termination (et) visit (14 and 28 days post-last dose)
This trial's timeline: 3 weeks for screening, Varies for treatment, and until follow-up (fu) visit/early termination (et) visit (14 and 28 days post-last dose) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part A and Part B: Number of subjects with adverse events
Other outcome measures
Pharmacokinetic parameters of SM17 in healthy subjects
Pharmacokinetic parameters of SM17 in healthy subjects: time to peak (Tmax)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Drug SM17Experimental Treatment1 Intervention
Peripheral intravenous injection
Group II: Drug PlaceboPlacebo Group1 Intervention
Peripheral intravenous injection

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

SinoMab BioScience LtdLead Sponsor
4 Previous Clinical Trials
754 Total Patients Enrolled

Media Library

Placebo (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05332834 — Phase 1
Asthma Research Study Groups: Drug Placebo, Drug SM17
Asthma Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT05332834 — Phase 1
Placebo (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05332834 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings left for volunteers in this experiment?

"Per clinicaltrials.gov, the original posting of this research trial was on April 1st 2022 and latest edition occurred on April 18th 2022. At present no additional participants are needed for the study; however, there is one other medical experiment accepting enrollees."

Answered by AI

Has SM17 been officially sanctioned by the FDA?

"SM17 is a new intervention, so it has been given a safety score of 1. This reflects the fact that this clinical trial is in its first phase and limited data exists regarding both efficacy and safety."

Answered by AI

Can those over 60 years of age join this research endeavor?

"This medical trial is open to participants that are younger than 55 and have passed the age of majority."

Answered by AI

How can I become a participant in this clinical research?

"This clinical trial, which is accepting 78 participants, requires that patients have a diagnosis of asthma and are aged between 19 to 55 years old."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects
2022. "A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05332834.
~28 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top